|
Post by guruzim on Feb 18, 2015 22:09:05 GMT
note I'm not saying any of these are the reason - I'm saying any of them could be in play with the (lack of) information we have available.
|
|
|
Post by imz72 on May 13, 2015 18:18:53 GMT
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM, May 13, 2015 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2015 of 6.24 million shekels (approximately $1.61 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen® for geographic atrophy (GA), the severe stage of the dry form of age-related macular degeneration (dry-AMD). The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the U.S. Food and Drug Administration (FDA) and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens. Details of the trial are available at clinicaltrials.gov/. Cell Cure expects to report interim data from the cohorts in the coming months.
“We thank the Israel Office of the Chief Scientist for its commitment to innovation and for continuing support of Cell Cure and its development of a cell therapy-based treatment for a major disease of aging,” said Charles Irving, PhD, Chief Executive Officer of Cell Cure. “I join with Dr. Irving in thanking the OCS for their generous support in advancing pluripotent stem cell research into clinical applications,” said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure, Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel. The OCS has previously supported Cell Cure, providing grants of approximately $8 million since 2007, including the latest award. Under the grant award agreement, Cell Cure is obligated to pay a 3.5% royalty to the OCS on revenues from OpRegen® up to an amount equal to 100% of the grants received plus interest at a LIBOR rate. Several BioTime subsidiaries, including Cell Cure, continue to fund their operations not only through support from BioTime but also by raising capital from outside investors, receiving grants, and generating revenues. investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-newsArticle_pf&id=2047497
|
|
|
Post by imz72 on Jul 14, 2015 11:35:48 GMT
Cell Cure just informed the Tel-Aviv Stock Exchange that they got a patent in the US for culturing ESC. I expect a PR from BioTime to follow soon. Meanwhile here is the patent. (Edit: it's not an RPE patent as I initially wrote). Google translation of the announcement in Hebrew: HBL - Hadasit Bio-Holdings Ltd. ("The Company") July 14, 2015 To: Israel Securities Authority www.isa.gov.ilTo: Tel Aviv Stock Exchange Ltd. in Tel Aviv http://www.tase.co.il Re: a US patent of Cell Cure Neurosciences The company is pleased to announce that Cell Cure Neurosciences Ltd., a company held in 21.2% by the company received a US patent entitled: METHODS OF CULTURING EMBRYONIC STEM CELLS AND CONTROLLED DIFFERENTIATION (US Patent No. 9080147) The patent is owned by ES Cell International which has granted Cell Cure an exclusive license to use the patent. . The patent relates to methods for directing the differentiation and ripening of embryonic stem cells and is important for protecting Cell Cure technology to create adult cells such as nerve cells for transplantation and regeneration. The patent is valid until June 20, 2021. Sincerely, HBL - Hadasit Bio-Holdings Ltd.
|
|